Back to search results

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Grade 3b Follicular Lymphoma · Recurrent High Grade B-Cell Lymphoma · Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma · Recurrent Transformed Chronic Lymphocytic Leukemia · Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma · Refractory Grade 3b Follicular Lymphoma · Refractory High Grade B-Cell Lymphoma · Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma · Refractory Transformed Chronic Lymphocytic Leukemia · Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope Medical Center, Duarte, California, United States

    Contact: Study coordinator (Swetha Kambhampati) · skambhampati@coh.org · 626-256-4673
    Contact: Principal Investigator (Swetha Kambhampati)
Study leads

  • Swetha Kambhampati

    Principal Investigator

    City of Hope Medical Center

View source on ClinicalTrials.gov(opens in a new tab)